|
US7238673B2
(en)
|
1989-03-31 |
2007-07-03 |
The Regents Of The University Of Michigan |
Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
|
|
US7745416B2
(en)
*
|
1995-04-11 |
2010-06-29 |
The Regents Of The University Of California |
Method for in vivo regulation of cardiac muscle contractility
|
|
CA2223837C
(fr)
*
|
1995-06-07 |
2010-05-25 |
University Of North Carolina At Chapel Hill |
Transduction de myoblastes par vecteurs de virus adeno-associes
|
|
US20010009904A1
(en)
*
|
1997-12-30 |
2001-07-26 |
Jon A. Wolff |
Process of delivering a polynucleotide to a cell via the vascular system
|
|
US20060088938A1
(en)
*
|
1995-12-15 |
2006-04-27 |
Mitchell Lloyd G |
Methods and compositions for use in spliceosome mediated RNA trans-splicing in plants
|
|
US20020193580A1
(en)
*
|
1995-12-15 |
2002-12-19 |
Mitchell Lloyd G. |
Methods and compositions for use in spliceosome mediated RNA trans-splicing
|
|
US20030027250A1
(en)
*
|
1995-12-15 |
2003-02-06 |
Mitchell Lloyd G. |
Methods and compositions for use in spliceosome mediated RNA trans-splicing
|
|
US5846528A
(en)
*
|
1996-01-18 |
1998-12-08 |
Avigen, Inc. |
Treating anemia using recombinant adeno-associated virus virions comprising an EPO DNA sequence
|
|
US5962313A
(en)
*
|
1996-01-18 |
1999-10-05 |
Avigen, Inc. |
Adeno-associated virus vectors comprising a gene encoding a lyosomal enzyme
|
|
US5858351A
(en)
*
|
1996-01-18 |
1999-01-12 |
Avigen, Inc. |
Methods for delivering DNA to muscle cells using recombinant adeno-associated virus vectors
|
|
US5866552A
(en)
*
|
1996-09-06 |
1999-02-02 |
The Trustees Of The University Of Pennsylvania |
Method for expressing a gene in the absence of an immune response
|
|
CA2264483C
(fr)
*
|
1996-09-06 |
2011-03-22 |
James M. Wilson |
Methode de therapie genique basee sur des virus adeno-associes de recombinaison
|
|
US20020037867A1
(en)
*
|
1999-02-26 |
2002-03-28 |
James M. Wilson |
Method for recombinant adeno-associated virus-directed gene therapy
|
|
US6242426B1
(en)
*
|
1997-07-25 |
2001-06-05 |
Avigen, Inc. |
Induction of immune response to antigens expressed by recombinant adeno-associated virus
|
|
JP2001512142A
(ja)
*
|
1997-07-31 |
2001-08-21 |
カイロン コーポレイション |
宿主の免疫抑制を介するａａｖベクターの再投与を可能にする方法
|
|
US6989264B2
(en)
*
|
1997-09-05 |
2006-01-24 |
Targeted Genetics Corporation |
Methods for generating high titer helper-free preparations of released recombinant AAV vectors
|
|
US6346415B1
(en)
|
1997-10-21 |
2002-02-12 |
Targeted Genetics Corporation |
Transcriptionally-activated AAV inverted terminal repeats (ITRS) for use with recombinant AAV vectors
|
|
IL135578A0
(en)
*
|
1997-10-29 |
2001-05-20 |
Genzyme Corp |
Compositions and methods for treating lysosomal storage disease
|
|
US6953690B1
(en)
|
1998-03-20 |
2005-10-11 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for helper-free production of recombinant adeno-associated viruses
|
|
US6759237B1
(en)
|
1998-11-05 |
2004-07-06 |
The Trustees Of The University Of Pennsylvania |
Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
|
|
EP1135468B1
(fr)
*
|
1998-11-10 |
2010-01-06 |
University Of North Carolina At Chapel Hill |
Vecteurs viraux et leurs procedes d'elaboration et d'administration
|
|
US6303362B1
(en)
*
|
1998-11-19 |
2001-10-16 |
The Board Of Trustees Of The Leland Stanford Junior University |
Adenoviral vector and methods for making and using the same
|
|
AU1557000A
(en)
*
|
1998-11-20 |
2000-06-13 |
Autonomous University of Barcelona, The |
Insulin production by engineered muscle cells
|
|
US7078387B1
(en)
|
1998-12-28 |
2006-07-18 |
Arch Development Corp. |
Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors
|
|
US6509150B1
(en)
*
|
1999-03-05 |
2003-01-21 |
Universite De Nantes |
Compositions and methods for recombinant Adeno-Associated Virus production
|
|
JP4693244B2
(ja)
|
1999-03-18 |
2011-06-01 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
組換えアデノ随伴ウイルスのヘルパー無しの生産のための組成物および方法
|
|
AU1775901A
(en)
|
1999-11-17 |
2001-05-30 |
Avigen, Inc. |
Recombinant adeno-associated virus virions for the treatment of lysosomal disorders
|
|
US20040204379A1
(en)
*
|
2000-06-19 |
2004-10-14 |
Cheng Seng H. |
Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
|
|
US20040126774A1
(en)
*
|
2001-01-08 |
2004-07-01 |
Mitchell Lioyd G. |
Correction of factor VIII genetic defects using spliceosome mediated RNA trans splicing
|
|
AU2002258747A1
(en)
*
|
2001-04-09 |
2002-10-21 |
The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Synthesis and secretion of recombinant lysosomal enzymes by liver
|
|
CA2457694A1
(fr)
*
|
2001-08-09 |
2003-02-20 |
Cornell Research Foundation, Inc. |
Protection du facteur de croissance derive de plaquettes du myocarde
|
|
EP1427816A4
(fr)
|
2001-09-18 |
2004-12-01 |
Clontech Lab Inc |
Procede de producteur dde vecteurs adenoviraux s'appuyant sur une recombinase specifique d'un site
|
|
US7399753B2
(en)
*
|
2002-02-25 |
2008-07-15 |
Virxsys Corporation |
Trans-splicing mediated photodynamic therapy
|
|
AU2003223497A1
(en)
*
|
2002-04-05 |
2003-10-27 |
Centocor, Inc. |
Asthma-related anti-il-13 immunoglobulin derived proteins, compositions, methods and uses
|
|
AU2003223775A1
(en)
*
|
2002-04-30 |
2003-11-17 |
Duke University |
Adeno-associated viral vectors and methods for their production from hybrid adenovirus and for their use
|
|
US20030223966A1
(en)
*
|
2002-04-30 |
2003-12-04 |
Fraites Thomas J. |
Treatment for pompe disease
|
|
EP1504016A4
(fr)
*
|
2002-05-08 |
2006-11-22 |
Intronn Inc |
Recours a la technique smart pour rendre des adenovirus capables de replication selective des cellules
|
|
ATE471387T1
(de)
*
|
2002-10-23 |
2010-07-15 |
Virxsys Corp |
Screening-verfahren zur identifizierung wirksamer prä-trans-spleissmoleküle
|
|
US7803365B2
(en)
*
|
2002-12-02 |
2010-09-28 |
Biovec, Llc |
Ex vivo and in vivo expression of the thrombomodulin gene for the treatment of cardiovascular and peripheral vascular diseases
|
|
US9388427B2
(en)
*
|
2002-12-02 |
2016-07-12 |
Biovec, Llc |
In vivo and ex vivo gene transfer into renal tissue using gutless adenovirus vectors
|
|
JP5433133B2
(ja)
*
|
2003-01-22 |
2014-03-05 |
デューク・ユニヴァーシティ |
リソソームポリペプチドを発現するための改善された構築物
|
|
CA2515916A1
(fr)
*
|
2003-02-25 |
2004-09-10 |
Biovec B.V. |
Applications therapeutiques du gene de la thrombomoduline au moyen de vecteurs viraux et non viraux
|
|
CA2530738C
(fr)
|
2003-06-24 |
2020-01-21 |
Genomic Health, Inc. |
Prediction de probabilite de la recurrence d'un cancer
|
|
US8007778B2
(en)
*
|
2003-07-01 |
2011-08-30 |
The Regents Of The University Of California |
Use of calcium binding proteins to improve cardiac contractile function
|
|
CA2545435C
(fr)
*
|
2003-11-12 |
2014-08-19 |
Amicus Therapeutics Inc. |
Derives d'hydroxy-piperidine pour traiter la maladie de gaucher
|
|
US7129049B2
(en)
*
|
2003-12-22 |
2006-10-31 |
Regents Of The University Of Minnesota |
Method of detecting equine glycogen storage disease IV
|
|
EP1716165A4
(fr)
*
|
2004-01-23 |
2008-06-18 |
Virxsys Corp |
Expression d'apoliproteine a1 (apoa-1) et variants au moyen de transepissage d'arn induit par complexe d'epissage
|
|
US7968334B2
(en)
*
|
2004-01-23 |
2011-06-28 |
Virxsys Corporation |
Expression of apoAI and variants thereof using spliceosome mediated RNA trans-splicing
|
|
US8053232B2
(en)
*
|
2004-01-23 |
2011-11-08 |
Virxsys Corporation |
Correction of alpha-1-antitrypsin genetic defects using spliceosome mediated RNA trans splicing
|
|
US20060078542A1
(en)
*
|
2004-02-10 |
2006-04-13 |
Mah Cathryn S |
Gel-based delivery of recombinant adeno-associated virus vectors
|
|
WO2005116224A2
(fr)
*
|
2004-05-18 |
2005-12-08 |
Children's Memorial Hospital |
Vecteurs viraux adeno-associes regules par la tetracycline pour l'administration de gene au systeme nerveux
|
|
US20060094110A1
(en)
*
|
2004-07-30 |
2006-05-04 |
Mcgarrity Gerard J |
Use of spliceosome mediated RNA trans-splicing for immunotherapy
|
|
US20060134658A1
(en)
*
|
2004-08-09 |
2006-06-22 |
Garcia-Blanco Mariano A |
Use of RNA trans-splicing for generation of interfering RNA molecules
|
|
DE102004047492B4
(de)
*
|
2004-09-23 |
2006-07-20 |
Jost-Werke Gmbh & Co. Kg |
Verfahren zum Übertragen von elektrischer, pneumatischer oder hydraulischer Energie sowie ein Energieübertragungssystem
|
|
US7871795B2
(en)
|
2004-10-08 |
2011-01-18 |
Virxsys Corporation |
Targeted trans-splicing of highly abundant transcripts for in vivo production of recombinant proteins
|
|
CA2583306A1
(fr)
*
|
2004-10-08 |
2006-08-10 |
Intronn, Inc. |
Utilisation d'un trans-epissage d'arn pour le transfert genique d'anticorps et la production polypeptidique d'anticorps
|
|
WO2006066066A2
(fr)
*
|
2004-12-15 |
2006-06-22 |
University Of North Carolina At Chapel Hill |
Vecteurs chimeriques
|
|
JP5623740B2
(ja)
*
|
2006-07-25 |
2014-11-12 |
セラドン・コーポレーション |
遺伝子治療用アデノ随伴ウイルスベクターの長期順行性の心外膜冠動脈注入
|
|
US20120322861A1
(en)
|
2007-02-23 |
2012-12-20 |
Barry John Byrne |
Compositions and Methods for Treating Diseases
|
|
AU2008218109A1
(en)
*
|
2007-02-23 |
2008-08-28 |
University Of Florida Research Foundation, Inc. |
Compositions and methods for treating glycogen storage diseases
|
|
EP2244740A1
(fr)
*
|
2008-02-19 |
2010-11-03 |
Celladon Corporation |
Compositions pour un captage amélioré de vecteurs viraux dans le myocarde
|
|
DK2659904T3
(en)
|
2008-06-26 |
2015-12-07 |
Orphazyme Aps |
Use of Hsp70 as a regulator of enzymatic activity
|
|
WO2010093784A2
(fr)
|
2009-02-11 |
2010-08-19 |
The University Of North Carolina At Chapel Hill |
Vecteurs viraux modifiés et procédés de fabrication et d'utilisation de ceux-ci
|
|
EP3626255A1
(fr)
|
2010-11-30 |
2020-03-25 |
Orphazyme A/S |
Verfahren zur erhöhung der intrazellulären aktivität von hsp70
|
|
EP3613852A3
(fr)
|
2011-07-22 |
2020-04-22 |
President and Fellows of Harvard College |
Évaluation et amélioration de la spécificité de clivage des nucléases
|
|
CN104619354A
(zh)
|
2012-06-19 |
2015-05-13 |
佛罗里达大学研究基金会有限公司 |
用于治疗糖尿病的组合物和方法
|
|
US9163284B2
(en)
|
2013-08-09 |
2015-10-20 |
President And Fellows Of Harvard College |
Methods for identifying a target site of a Cas9 nuclease
|
|
US9359599B2
(en)
|
2013-08-22 |
2016-06-07 |
President And Fellows Of Harvard College |
Engineered transcription activator-like effector (TALE) domains and uses thereof
|
|
US9388430B2
(en)
|
2013-09-06 |
2016-07-12 |
President And Fellows Of Harvard College |
Cas9-recombinase fusion proteins and uses thereof
|
|
US9526784B2
(en)
|
2013-09-06 |
2016-12-27 |
President And Fellows Of Harvard College |
Delivery system for functional nucleases
|
|
US9340799B2
(en)
|
2013-09-06 |
2016-05-17 |
President And Fellows Of Harvard College |
MRNA-sensing switchable gRNAs
|
|
US9068179B1
(en)
|
2013-12-12 |
2015-06-30 |
President And Fellows Of Harvard College |
Methods for correcting presenilin point mutations
|
|
US20170049887A1
(en)
|
2014-04-25 |
2017-02-23 |
University Of Florida Research Foundation, Inc. |
Methods of permitting a subject to receive multiple doses of recombinant adeno-associated virus
|
|
WO2015191508A1
(fr)
|
2014-06-09 |
2015-12-17 |
Voyager Therapeutics, Inc. |
Capsides chimériques
|
|
EP4079847A1
(fr)
|
2014-07-30 |
2022-10-26 |
President And Fellows Of Harvard College |
Protéines cas9 comprenant des intéines dépendant de ligands
|
|
RU2745292C2
(ru)
|
2014-09-15 |
2021-03-23 |
Орпхазиме А/C |
Состав с аримокломолом
|
|
EP3215191B1
(fr)
|
2014-11-05 |
2024-08-14 |
Voyager Therapeutics, Inc. |
Polynucléotides codant pour la dopa décarboxylase et destinés au traitement de la maladie de parkinson
|
|
US10597660B2
(en)
|
2014-11-14 |
2020-03-24 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
|
|
KR102584655B1
(ko)
|
2014-11-14 |
2023-10-06 |
보이저 테라퓨틱스, 인크. |
조절성 폴리뉴클레오티드
|
|
WO2016081927A2
(fr)
|
2014-11-21 |
2016-05-26 |
University Of Florida Research Foundation, Inc. |
Vecteurs viraux adéno-associés recombinés au génome modifié
|
|
EP3230441A4
(fr)
|
2014-12-12 |
2018-10-03 |
Voyager Therapeutics, Inc. |
Compositions et méthodes pour la production de scaav
|
|
WO2016179497A1
(fr)
|
2015-05-07 |
2016-11-10 |
Shire Human Genetic Therapies, Inc. |
Thérapie génique par glucocérébrosidase pour la maladie de parkinson
|
|
CN108699116A
(zh)
|
2015-10-23 |
2018-10-23 |
哈佛大学的校长及成员们 |
用于基因编辑的演化的cas9蛋白
|
|
US10983110B2
(en)
|
2015-12-02 |
2021-04-20 |
Voyager Therapeutics, Inc. |
Assays for the detection of AAV neutralizing antibodies
|
|
WO2017178029A1
(fr)
|
2016-04-13 |
2017-10-19 |
Orphazyme Aps |
Protéines de choc thermique et homéostasie du cholestérol
|
|
BR112018071180A2
(pt)
|
2016-04-16 |
2019-02-12 |
University Of Florida Research Foundation, Incorporated |
métodos de reforço potência biológica de baculovirus system-produzido vírus adeno-associado recombinante
|
|
US11326182B2
(en)
|
2016-04-29 |
2022-05-10 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
|
US11299751B2
(en)
|
2016-04-29 |
2022-04-12 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
|
US20190111041A1
(en)
|
2016-04-29 |
2019-04-18 |
Orphazyme A/S |
Arimoclomol for treating glucocerebrosidase associated disorders
|
|
AU2017267665C1
(en)
|
2016-05-18 |
2023-10-05 |
Voyager Therapeutics, Inc. |
Modulatory polynucleotides
|
|
US11951121B2
(en)
|
2016-05-18 |
2024-04-09 |
Voyager Therapeutics, Inc. |
Compositions and methods for treating Huntington's disease
|
|
CA3032699A1
(fr)
|
2016-08-03 |
2018-02-08 |
President And Fellows Of Harvard College |
Editeurs de nucleobases d'adenosine et utilisations associees
|
|
CA3033327A1
(fr)
|
2016-08-09 |
2018-02-15 |
President And Fellows Of Harvard College |
Proteines de fusion cas9-recombinase programmables et utilisations associees
|
|
WO2018039438A1
(fr)
|
2016-08-24 |
2018-03-01 |
President And Fellows Of Harvard College |
Incorporation d'acides aminés non naturels dans des protéines au moyen de l'édition de bases
|
|
EP3506817A4
(fr)
|
2016-08-30 |
2020-07-22 |
The Regents of The University of California |
Procédés de ciblage et d'administration biomédicaux, et dispositifs et systèmes pour la mise en oeuvre de ceux-ci
|
|
SG11201903089RA
(en)
|
2016-10-14 |
2019-05-30 |
Harvard College |
Aav delivery of nucleobase editors
|
|
WO2018119359A1
(fr)
|
2016-12-23 |
2018-06-28 |
President And Fellows Of Harvard College |
Édition du gène récepteur ccr5 pour protéger contre l'infection par le vih
|
|
AU2018224044B2
(en)
|
2017-02-21 |
2024-01-25 |
The Uab Research Foundation |
Modified AAV capsid proteins and uses thereof
|
|
US11898179B2
(en)
|
2017-03-09 |
2024-02-13 |
President And Fellows Of Harvard College |
Suppression of pain by gene editing
|
|
US11542496B2
(en)
|
2017-03-10 |
2023-01-03 |
President And Fellows Of Harvard College |
Cytosine to guanine base editor
|
|
AU2018240571B2
(en)
|
2017-03-23 |
2024-11-07 |
President And Fellows Of Harvard College |
Nucleobase editors comprising nucleic acid programmable DNA binding proteins
|
|
CN119491003A
(zh)
|
2017-05-05 |
2025-02-21 |
沃雅戈治疗公司 |
治疗亨廷顿病的组合物和方法
|
|
SG11201909870SA
(en)
|
2017-05-05 |
2019-11-28 |
Voyager Therapeutics Inc |
Compositions and methods of treating amyotrophic lateral sclerosis (als)
|
|
WO2018209320A1
(fr)
|
2017-05-12 |
2018-11-15 |
President And Fellows Of Harvard College |
Arn guides incorporés par aptazyme pour une utilisation avec crispr-cas9 dans l'édition du génome et l'activation transcriptionnelle
|
|
MA50546A
(fr)
|
2017-06-07 |
2020-09-16 |
Regeneron Pharma |
Compositions et méthodes pour l'internalisation d'enzymes
|
|
JOP20190269A1
(ar)
|
2017-06-15 |
2019-11-20 |
Voyager Therapeutics Inc |
بولي نوكليوتيدات aadc لعلاج مرض باركنسون
|
|
CN111132626B
(zh)
|
2017-07-17 |
2024-01-30 |
沃雅戈治疗公司 |
轨迹阵列引导系统
|
|
EP3658573A1
(fr)
|
2017-07-28 |
2020-06-03 |
President and Fellows of Harvard College |
Procédés et compositions pour l'évolution d'éditeurs de bases à l'aide d'une évolution continue assistée par phage (pace)
|
|
CN111448308A
(zh)
|
2017-08-03 |
2020-07-24 |
沃雅戈治疗公司 |
递送aav的组合物和方法
|
|
US11319532B2
(en)
|
2017-08-30 |
2022-05-03 |
President And Fellows Of Harvard College |
High efficiency base editors comprising Gam
|
|
US20200263199A1
(en)
|
2017-09-29 |
2020-08-20 |
Voyager Therapeutics, Inc. |
Rescue of central and peripheral neurological phenotype of friedreich's ataxia by intravenous delivery
|
|
US20200237799A1
(en)
|
2017-10-16 |
2020-07-30 |
Voyager Therapeutics, Inc. |
Treatment of amyotrophic lateral sclerosis (als)
|
|
CN111479924B
(zh)
|
2017-10-16 |
2024-06-14 |
沃雅戈治疗公司 |
肌萎缩性侧索硬化症(als)的治疗
|
|
CA3082251A1
(fr)
|
2017-10-16 |
2019-04-25 |
The Broad Institute, Inc. |
Utilisations d'editeurs de bases adenosine
|
|
CA3090519A1
(fr)
|
2018-02-07 |
2019-08-15 |
Regeneron Pharmaceuticals, Inc. |
Procedes et compositions pour l'administration de proteines therapeutiques
|
|
CN112041442A
(zh)
|
2018-02-28 |
2020-12-04 |
北卡罗来纳大学查佩尔希尔分校 |
用于逃避抗体的病毒载体的方法和组合物
|
|
AU2019247748A1
(en)
|
2018-04-03 |
2020-10-08 |
Ginkgo Bioworks, Inc. |
Antibody-evading virus vectors
|
|
AU2019247746B2
(en)
|
2018-04-03 |
2024-08-15 |
Ginkgo Bioworks, Inc. |
Antibody-evading virus vectors
|
|
US12116384B2
(en)
|
2018-04-03 |
2024-10-15 |
Ginkgo Bioworks, Inc. |
Virus vectors for targeting ophthalmic tissues
|
|
WO2019222663A1
(fr)
|
2018-05-17 |
2019-11-21 |
Regeneron Pharmaceuticals, Inc. |
Anticorps anti-cd63, conjugués et leurs utilisations
|
|
WO2019226953A1
(fr)
|
2018-05-23 |
2019-11-28 |
The Broad Institute, Inc. |
Éditeurs de bases et leurs utilisations
|
|
AU2019282822A1
(en)
|
2018-06-08 |
2020-11-26 |
University Of Florida Research Foundation, Incorporated |
AAV cardiac gene therapy for cardiomyopathy
|
|
JP2021528959A
(ja)
|
2018-06-22 |
2021-10-28 |
アスクレピオス バイオファーマシューティカル， インコーポレイテッド |
細胞内で存続する遺伝子送達のためのベクター
|
|
JP7528066B2
(ja)
|
2018-09-28 |
2024-08-05 |
ボイジャー セラピューティクス インコーポレイテッド |
操作されたプロモータを有するフラタキシン発現コンストラクトおよびその使用方法
|
|
WO2020092453A1
(fr)
|
2018-10-29 |
2020-05-07 |
The Broad Institute, Inc. |
Éditeurs de nucléobases comprenant geocas9 et utilisations associées
|
|
US20240417753A1
(en)
|
2019-03-19 |
2024-12-19 |
The Broad Institute, Inc. |
Methods and compositions for editing nucleotide sequences
|
|
TW202102525A
(zh)
|
2019-03-21 |
2021-01-16 |
美商史崔德生物公司 |
重組腺相關病毒載體
|
|
WO2020210751A1
(fr)
|
2019-04-12 |
2020-10-15 |
The Broad Institute, Inc. |
Système pour édition génomique
|
|
WO2020236982A1
(fr)
|
2019-05-20 |
2020-11-26 |
The Broad Institute, Inc. |
Administration d'aav d'éditeurs de nucléobases
|
|
WO2021072328A1
(fr)
|
2019-10-10 |
2021-04-15 |
The Broad Institute, Inc. |
Procédés et compositions pour le prime editing d'arn
|
|
KR20220083714A
(ko)
|
2019-10-17 |
2022-06-20 |
스트라이드바이오 인코포레이티드 |
니만-피크 질환 c형의 치료를 위한 아데노-연관 바이러스 벡터
|
|
BR112022022603A2
(pt)
|
2020-05-08 |
2023-01-17 |
Broad Inst Inc |
Métodos e composições para edição simultânea de ambas as fitas de sequência alvo de nucleotídeos de fita dupla
|
|
WO2022026410A2
(fr)
|
2020-07-27 |
2022-02-03 |
Voyager Therapeutics, Inc |
Compositions et méthodes pour le traitement de la maladie de niemann-pick de type c1
|
|
CN117120619A
(zh)
|
2020-07-27 |
2023-11-24 |
沃雅戈治疗公司 |
用于治疗与葡萄糖神经酰胺酶β缺陷相关的神经病症的组合物和方法
|
|
CN116745409A
(zh)
|
2020-08-19 |
2023-09-12 |
萨雷普塔治疗公司 |
用于治疗雷特综合征的腺相关病毒载体
|
|
JP2024500632A
(ja)
|
2020-11-19 |
2024-01-10 |
ゼブラ デンマーク エー／エス |
アリモクロモルクエン酸塩及びその中間体の調製プロセス
|
|
WO2022140402A1
(fr)
|
2020-12-23 |
2022-06-30 |
University Of Florida Research Foundation, Incorporated |
Efficacité accrue d'encapsidation de vecteur pour thérapie génique cardiaque
|
|
WO2023076898A1
(fr)
|
2021-10-25 |
2023-05-04 |
The Broad Institute, Inc. |
Procédés et compositions pour l'édition d'un génome à l'aide d'une édition primaire et d'une recombinase
|
|
US20250049955A1
(en)
|
2021-11-17 |
2025-02-13 |
Voyager Therapeutics, Inc. |
Compositons and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
|
|
AU2023248451A1
(en)
|
2022-04-04 |
2024-10-17 |
President And Fellows Of Harvard College |
Cas9 variants having non-canonical pam specificities and uses thereof
|
|
WO2023212715A1
(fr)
|
2022-04-28 |
2023-11-02 |
The Broad Institute, Inc. |
Vecteurs aav codant pour des éditeurs de base et utilisations associées
|
|
WO2023240236A1
(fr)
|
2022-06-10 |
2023-12-14 |
Voyager Therapeutics, Inc. |
Compositions et procédés pour le traitement de troubles liés à l'amyotrophie spinale
|
|
CN120019143A
(zh)
|
2022-08-16 |
2025-05-16 |
布罗德研究所股份有限公司 |
经进化的胞苷脱氨酶及使用其编辑dna的方法
|
|
WO2024108092A1
(fr)
|
2022-11-17 |
2024-05-23 |
The Broad Institute, Inc. |
Distribution d'éditeur primaire par vaa
|
|
WO2024163012A1
(fr)
|
2023-02-02 |
2024-08-08 |
Voyager Therapeutics, Inc. |
Compositions et méthodes de traitement de troubles neurologiques liés à un déficit en bêta glucosylcéramidase
|
|
WO2025090858A1
(fr)
|
2023-10-27 |
2025-05-01 |
Biogen Ma Inc. |
Procédés d'identification de variants de capside de vaa ayant des caractéristiques souhaitées
|